Our research indicated that the group of high risk obtained higher scores of TIM-3, PD-1, CTLA-4, and TIGIT, suggesting that PAPS could distinguish the HCC patients who had a higher response to immune checkpoint inhibitors. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.